Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push
What happened
The deal, at $36.50 per share, represents a roughly 45% premium and is expected to close by the end of 2026
Summary assembled by rule from the sources below
The deal, at $36.50 per share, represents a roughly 45% premium and is expected to close by the end of 2026
Summary assembled by rule from the sources below